We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Keryx Biopharmaceuticals, Inc. to Akebia Therapeutics, Inc. (“Akebia”) (NASDAQ GM: AKBA) Under the terms of the transaction, Keryx shareholders will receive 0.37433 common shares of Akebia for each share of Keryx they own.
The investigation concerns whether the Board of Keryx breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Akebia is underpaying for Keryx shares, thus unlawfully harming Keryx shareholders.
To receive more information, please fill out the form.